A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

Jeffrey D Greenberg; George Reed; Dennis Decktor; Leslie Harrold; Daniel Furst; Allan Gibofsky; Ralph DeHoratius; Mitsumasa Kishimoto; Joel M Kremer

doi:10.1136/annrheumdis-2011-150573

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Clinical and epidemiological research

Extended report

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Greenberg JD, Reed G, Decktor D, et al

A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry

Annals of the Rheumatic Diseases 2012;71:1134-1142.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password